title: Recent insights into farnesoid X receptor in non-alcoholic fatty liver disease.
abstract: Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of metabolic syndrome and is one of the most prevalent liver disorders worldwide. NAFLD can gradually progress to liver inflammation, fibrosis, cirrhosis and even hepatocellular carcinoma. However, the pathogenesis of NAFLD is complex, and no efficient pharmaceutic treatments have yet been established for NAFLD. Accumulating data have shown that the farnesoid X receptor (FXR) plays important roles not only in bile acid metabolism, but also in lipid and carbohydrate homeostasis, inflammatory responses, among others. In this review, we aim to highlight the role of FXR in the pathogenesis and treatment of NAFLD.
authors.affiliation: Jiao-Ya Xu, Zhong-Ping Li, Li Zhang, Guang Ji, Institute of Digestive Diseases, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China.
authors.forename: Jiao-Ya
authors.initials: JY
authors.lastname: Xu
authors.affiliation: Jiao-Ya Xu, Zhong-Ping Li, Li Zhang, Guang Ji, Institute of Digestive Diseases, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China.
authors.forename: Zhong-Ping
authors.initials: ZP
authors.lastname: Li
authors.affiliation: Jiao-Ya Xu, Zhong-Ping Li, Li Zhang, Guang Ji, Institute of Digestive Diseases, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China.
authors.forename: Li
authors.initials: L
authors.lastname: Zhang
authors.affiliation: Jiao-Ya Xu, Zhong-Ping Li, Li Zhang, Guang Ji, Institute of Digestive Diseases, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China.
authors.forename: Guang
authors.initials: G
authors.lastname: Ji
mesh_terms: D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D001647:Bile Acids and Salts / Q000378:metabolism; D050260:Carbohydrate Metabolism; D018450:Disease Progression; D006505:Hepatitis / Q000209:etiology / Q000378:metabolism; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D018836:Inflammation Mediators / Q000378:metabolism; D050356:Lipid Metabolism; D008099:Liver / Q000187:drug effects / Q000378:metabolism*; D008103:Liver Cirrhosis / Q000209:etiology / Q000378:metabolism; D065626:Non-alcoholic Fatty Liver Disease / Q000150:complications / Q000188:drug therapy / Q000378:metabolism*; D018160:Receptors, Cytoplasmic and Nuclear / Q000819:agonists / Q000378:metabolism*; D015398:Signal Transduction; D000099150:Receptor, Farnesoid X-Activated
chemical_list: D000893:Anti-Inflammatory Agents; D001647:Bile Acids and Salts; D000960:Hypolipidemic Agents; D018836:Inflammation Mediators; D018160:Receptors, Cytoplasmic and Nuclear; D000099150:Receptor, Farnesoid X-Activated
keywords: Farnesoid X receptor; Lipid metabolism; Mechanism; Non-alcoholic fatty liver disease; Therapy